Within bone, the mechanotransduction pathway is recognized as one of the primary pathways determining bone strength. However, despite an intense research effort over the last 30 years seeking to identify potential mechanosensing molecules in bone cells, only a handful of candidates have been identified. This is due in large part to the low throughput of existing mechanotransduction assays, which preclude them from powerful approaches for de novo discovery such as high-throughput screens and systems biology-based investigations.

This content is only available via PDF.
You do not currently have access to this content.